Drug coated stents for carotid intervention

Journal of Cardiovascular Surgery

Volumn 46, Issue 3, 2005, Pages 249-259

  Tepe, Gunnar ^a   Schmehl, J ^a   Claussen, C D ^a   Ernemann, U ^a   Pereira, P ^a   Duda, S H ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Jewish Hospital   (Germany)

Author keywords

Carotid artery stenosis; Drug elution; Endarterectomy; Paclitaxel; Restenosis; Sirolimus; Stents; Stroke

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; PACLITAXEL; RAPAMYCIN;

ANGIOPLASTY; ARTICLE; BRAIN PROTECTION; CAROTID ARTERY DISEASE; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; DEATH; DRUG ELUTING STENT; FOLLOW UP; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MINIMALLY INVASIVE SURGERY; PATIENT SELECTION; SAFETY; STROKE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID STENOSIS; CEREBROVASCULAR ACCIDENT; COATED MATERIALS, BIOCOMPATIBLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; PROSTHESIS DESIGN; RECURRENCE; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33646228301     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Spence D, Eliasziw M. Endarterectomy or angioplasty for treatment of carotid stenosis? Lancet 2001;357:1722-3.
2. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001;357:1729-37.
3. Dietz A, Berkefeld J, Theron JG, Schmitz-Rixen T, Zanella FE, Turowski B et al. Endovascular treatment of symptomatic carotid stenosis using stent placement: long-term follow-up of patients with a balanced surgical risk/benefit ratio. Stroke 2001;32:1855-9.
4. Hobson RW. CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status. Semin Vasc Surg 2000;13:139-43.
5. Yadav JS, Wholey MH, Kuntz RA, Fayad P, Katzen B, Mishkel GJ et al. for the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493-501.
6. Denny DF. Prediction of restenosis after carotid artery stent implantation. Radiology 2003;227:316-8.
7. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415-25.
8. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273:1421-8.
9. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004;363:1491-502.
10. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379-87.
11. Mas JL, Chatellier G, Beyssen B. Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S) trial. Stroke 2004;35:e18-e20.
12. Featherstone RL, Brown MM, Coward LJ. International carotid stenting study: protocol for a randomised clinical trial comparing carotid stenting with endarterectomy in symptomatic carotid artery stenosis. Cerebrovasc Dis 2004;18:69-74.
13. Carotid revascularization using endarterectomy or stenting systems (CARESS): phase I clinical trial. J Endovasc Ther 2003;10:1021-30.
14. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388-92.
15. Berkefeld J, Turowski B, Dietz A, Lanfermann H, Sitzer M, Schmitz-Rixen T et al. Recanalization results after carotid stent placement. Am J Neuroradiol 2002;23:113-20.
16. Christiaans MH, Ernst JM, Suttorp MJ, van den Berg JC, Overtoom TThC, Kelder JC et al. and on behalf of the Antonius carotid endarterectomy Angioplasty, and Stenting Study Group. Restenosis after carotid angioplasty and stenting: a follow-up study with duplex ultrasonography. Eur J Vasc Endovasc Surg 2003;26:141-4.
17. Schillinger M, Exner M, Mlekusch W, Haumer M, Ahmadi R, Rumpold H et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology 2002;224:529-35.
18. Toma N, Matsushima S, Murao K, Kawaguchi K, Imanaka-Yoshida K, Yoshida T et al. Histopathological findings in a human carotid artery after stent implantation. Case report. J Neurosurg 2003;98: 199-204.
19. Sousa JE, Costa MA, Abizaid A, Sousa AG, Peres F, Mattos LA et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24-7.
20. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002;359: 619-22.
21. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of resterrosis after coronary stenting in humans. Circulation 2002;105:2974-80.
22. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban-Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
23. Ruygrok PN, Melkert R, Morel MA, Ormiston JA, Bar FW, Fernandez-Aviles F et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol 1999;34:1507-11.
24. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7.
25. Chieffo A, Colombo A. Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions. Herz 2004;29:147-51.
26. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting, Stent (ELUTES) trial. Circulation 2004;109: 487-93.
27. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
28. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
29. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
30. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005;111:1040-4.
31. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C et al. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71.
32. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505-9.
33. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-8.
34. Duda SH, Poerner TC, Wiesinger B, Rundback JH, Tepe G, Wiskirchen J et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 2003;14:291-301.
35. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-506.
36. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano, M, Farb A et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-51.
37. Murray RR, Hewes RC, White RI, Mitchell SE, Auster M, Chang R et al. Long-segment femoropopliteal stenoses: is angioplasty a boon or a bust? Radiology 1987;162:473-6.
38. Riessen R, Oberhoff M, Karsch KR. [Concepts for local therapy of restenosis]. Z Kardiol 1996;85 Suppl 187-98. German.
39. Radke PW, vom-Dahl J, Klues HG. [Stent restenosis: therapy concepts and possibilities for prevention] Med Klin (Munich) 1999;94:88-92. German.
40. Phillips-Hughes J, Kandarpa K. Restenosis: pathophysiology and preventive strategies. J Vasc Interv Radiol 1996;7:321-33.
41. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ et al. A subgroup analysis of the Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial. Int J Radiat Oncol Biol Phys 1998;42:1097-104.
42. Serruys PW, Kay IP. I like the candy, I hate the wrapper: the (32)P radioactive stent. Circulation 2000;101:3-7.
43. Tepe G, Dinkelborg LM, Brehme U, Muschick P, Noll B, Dietrich T et al. Prophylaxis of restenosis with Re-186 labeled stents in a rabbit model. Circulation 2001;104:480-5.
44. Virmani R, Farb A, Carter AJ, Jones RM. Pathology of radiation-induced coronary artery disease in human and pig. Cardiovasc Radiat Med 1999;1:98-101.
45. Waksman R. Intracoronary brachytherapy in the Cath Lab. Physics dosimetry, technology and safety considerations. Herz 1998;23: 401-6.
46. Waksman R, Ajani AE, White RL, Pinnow E, Dieble R, Bui AB et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis; Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001;103:2332-5.
47. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 1992;86:100-10.
48. Tepe G, Duda SH, Kalinowski M, Kamenz J, Brehme U, Hanke H et al. Local intra-arterial drug delivery for prevention of restenosis. Comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter. Invest Radiol 2001;36:245-9.
49. Tepe G, Duda SH, Hanke H, Schulze S, Hagmeier S, Bruck B et al. Covered stents for prevention of restenosis. Experimental and clinical results with different stent designs. Invest Radiol 1996;31: 223-9.
50. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation 2002;106:2859-66.
51. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.
52. Virmani R, Farb A, Kolodgie FD. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz 2002;27:1-6.
53. Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 2003;16:485-90.
54. Toutouzas K, Di Mario C, Falotico R, Takagi T, Stankovic G, Albiero R et al. Sirolimus-eluting stents: a review of experimental and clinical findings. Z Kardiol 2002;91 Suppl 3:49-57.
55. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-3.
56. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
57. Grube E, Bullesfeld L. Initial experience with paclitaxel-coated stents. J Interv Cardiol 2002;15:471-5.
58. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle, Circulation 1999;99:2164-70.
59. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
60. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005;111:2326-9.
61. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
62. Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-40.
63. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
64. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
65. Ouriel K. Leadership challenges for carotid disease in the 21st century. Cardiovasc Surg 2003;11:255-6.